fresenius medical care ag - FMS

FMS

Close Chg Chg %
22.35 0.06 0.25%

Closed Market

22.41

+0.06 (0.25%)

Volume: 329.83K

Last Updated:

Apr 2, 2026, 3:59 PM EDT

Company Overview: fresenius medical care ag - FMS

FMS Key Data

Open

$22.08

Day Range

21.95 - 22.45

52 Week Range

20.95 - 30.42

Market Cap

$12.52B

Shares Outstanding

558.58M

Public Float

558.16M

Beta

0.87

Rev. Per Employee

N/A

P/E Ratio

11.82

EPS

$1.92

Yield

254.36%

Dividend

$0.57

EX-DIVIDEND DATE

May 23, 2025

SHORT INTEREST

N/A

AVERAGE VOLUME

541.84K

 

FMS Performance

1 Week
 
1.59%
 
1 Month
 
-2.35%
 
3 Months
 
-4.68%
 
1 Year
 
-6.35%
 
5 Years
 
-38.94%
 

FMS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 19
Full Ratings ➔

About fresenius medical care ag - FMS

Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. It operates through the Care Enablement and Care Delivery segments. The Care Enablement segment is involved in the healthcare products business including research and development, manufacturing, supply chain, and commercial operations as well as supporting functions, such as regulatory and quality management. The Care Delivery segment focuses on the health care services for the treatment of CKD, ESRD, and other extracorporeal therapies, including value and risk-based care programs. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

FMS At a Glance

Fresenius Medical Care AG
Else-Kröner-Strasse 1
Bad Homburg, Hessen 61352
Phone 49-6172-609-0 Revenue 22.16B
Industry Medical/Nursing Services Net Income 1.10B
Sector Health Services 2025 Sales Growth 5.948%
Fiscal Year-end 12 / 2026 Employees 111,024
View SEC Filings

FMS Valuation

P/E Current 11.82
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 12.564
Price to Sales Ratio 0.626
Price to Book Ratio 0.851
Price to Cash Flow Ratio 4.58
Enterprise Value to EBITDA 6.793
Enterprise Value to Sales 1.158
Total Debt to Enterprise Value 0.494

FMS Efficiency

Revenue/Employee 199,612.112
Income Per Employee 9,945.268
Receivables Turnover 5.259
Total Asset Turnover 0.623

FMS Liquidity

Current Ratio 1.254
Quick Ratio 0.889
Cash Ratio 0.276

FMS Profitability

Gross Margin 25.657
Operating Margin 9.597
Pretax Margin 6.777
Net Margin 4.982
Return on Assets 3.103
Return on Equity 7.187
Return on Total Capital 3.90
Return on Invested Capital 4.336

FMS Capital Structure

Total Debt to Total Equity 81.11
Total Debt to Total Capital 44.785
Total Debt to Total Assets 34.822
Long-Term Debt to Equity 64.601
Long-Term Debt to Total Capital 35.669
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Fresenius Medical Care Ag - FMS

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
20.38B 21.03B 20.92B 22.16B
Sales Growth
-2.12% +3.18% -0.55% +5.95%
Cost of Goods Sold (COGS) incl D&A
14.80B 15.70B 15.76B 16.48B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.81B 1.74B 1.66B 1.65B
Depreciation
1.63B 1.58B 1.51B 1.49B
Amortization of Intangibles
177.63M 164.69M 148.39M 159.38M
COGS Growth
-0.14% +6.04% +0.42% +4.51%
Gross Income
5.58B 5.33B 5.15B 5.69B
Gross Income Growth
-7.00% -4.42% -3.39% +10.35%
Gross Profit Margin
+27.38% +25.36% +24.63% +25.66%
2022 2023 2024 2025 5-year trend
SG&A Expense
3.74B 3.62B 3.37B 3.56B
Research & Development
240.28M 250.79M 198.48M 178.29M
Other SG&A
3.50B 3.37B 3.18B 3.38B
SGA Growth
+2.72% -3.20% -6.72% +5.48%
Other Operating Expense
- - - -
-
Unusual Expense
444.27M 318.27M 527.05M 38.86M
EBIT after Unusual Expense
1.40B 1.40B 1.25B 2.09B
Non Operating Income/Expense
177.60M 30.54M 175.58M (186.14M)
Non-Operating Interest Income
69.69M 93.95M 76.00M 77.27M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
364.84M 443.14M 429.50M 399.81M
Interest Expense Growth
-12.34% +21.46% -3.08% -6.91%
Gross Interest Expense
367.19M 445.84M 431.82M 401.59M
Interest Capitalized
2.35M 2.70M 2.32M 1.78M
Pretax Income
1.21B 985.14M 997.37M 1.50B
Pretax Income Growth
-30.73% -18.68% +1.24% +50.59%
Pretax Margin
+5.94% +4.68% +4.77% +6.78%
Income Tax
341.52M 324.94M 341.87M 362.24M
Income Tax - Current - Domestic
(5.70M) 22.65M 75.69M 51.88M
Income Tax - Current - Foreign
390.80M 434.35M 344.80M 341.07M
Income Tax - Deferred - Domestic
17.83M 36.78M (40.85M) 12.45M
Income Tax - Deferred - Foreign
(61.41M) (168.83M) (37.76M) (43.16M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
939.91M 791.87M 801.39M 1.34B
Minority Interest Expense
232.18M 252.40M 219.54M 240.27M
Net Income
707.73M 539.47M 581.86M 1.10B
Net Income Growth
-38.23% -23.77% +7.86% +89.77%
Net Margin Growth
+3.47% +2.56% +2.78% +4.98%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
707.73M 539.47M 581.86M 1.10B
Preferred Dividends
- - - -
-
Net Income Available to Common
707.73M 539.47M 581.86M 1.10B
EPS (Basic)
1.2067 0.9193 0.9915 1.8959
EPS (Basic) Growth
-38.29% -23.82% +7.85% +91.22%
Basic Shares Outstanding
586.49M 586.83M 586.83M 582.38M
EPS (Diluted)
1.2067 0.9193 0.9915 1.8959
EPS (Diluted) Growth
-38.27% -23.82% +7.85% +91.22%
Diluted Shares Outstanding
586.49M 586.83M 586.83M 582.38M
EBITDA
3.65B 3.46B 3.44B 3.78B
EBITDA Growth
-13.81% -5.24% -0.59% +9.86%
EBITDA Margin
+17.91% +16.45% +16.44% +17.05%

Snapshot

Average Recommendation HOLD Average Target Price 25.593
Number of Ratings 19 Current Quarters Estimate 0.645
FY Report Date 06 / 2026 Current Year's Estimate 2.38
Last Quarter’s Earnings 0.54 Median PE on CY Estimate N/A
Year Ago Earnings 2.52 Next Fiscal Year Estimate 2.588
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 5 13 13
Mean Estimate 0.65 0.65 2.38 2.59
High Estimates 0.77 0.80 2.73 2.99
Low Estimate 0.57 0.55 2.28 2.20
Coefficient of Variance 13.50 14.43 4.59 7.17

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 6 6 6
OVERWEIGHT 0 0 0
HOLD 6 6 6
UNDERWEIGHT 3 3 3
SELL 4 4 4
MEAN Hold Hold Hold

Fresenius Medical Care Ag in the News